Chemed Corp Stock Price, News & Analysis

Chemed Corporation (NYSE:CHE) has declared a quarterly cash dividend of 38-cents per share, marking a 5.6% increase from the 36-cent dividend paid in June 2022. This dividend will be payable on September 2, 2022, to shareholders of record as of August 15, 2022. This is the 205^th consecutive quarterly dividend paid by Chemed since it became public 51 years ago. The company operates two subsidiaries: VITAS Healthcare and Roto-Rooter.

Chemed Corporation (NYSE: CHE) reported its financial results for Q2 2022, revealing a 0.2% decline in revenue to $531 million. GAAP diluted EPS increased 25.4% to $4.40. The VITAS segment faced challenges, with net patient revenue down 4.5% to $298 million and a 10.4% decrease in net income. In contrast, Roto-Rooter demonstrated growth with revenue up 6.0% to $233 million and an 8.8% rise in net income. Chemed's cash position stood at $9.6 million with $117 million in debt, while share repurchases remain a priority as approximately $125 million is left for buybacks.

Chemed Corporation (NYSE: CHE) will release its financial results for the second quarter ending June 30, 2022, on Wednesday, July 27, 2022, after market close. A conference call and webcast to discuss these results will take place on Thursday, July 28, 2022, at 10 a.m. ET. The call can be accessed through Chemed’s investor relations website, and a replay will be available two hours post-call. Chemed operates VITAS Healthcare, the largest provider of hospice care, and Roto-Rooter, a leading plumbing service.

Chemed Corporation (NYSE:CHE) has secured $550 million through amended and restated senior secured credit facilities. These facilities comprise a $450 million revolver and a $100 million term loan, both with a five-year term. The interest rate is based on a floating rate, typically the secured overnight financing rate (SOFR), plus a tiered rate dependent on Chemed's leverage ratio. Additionally, there is an expansion feature allowing for an increase of up to $250 million in the credit facilities, providing Chemed with financial flexibility.

Chemed Corporation (NYSE: CHE) will present at the Jefferies 2022 Healthcare Conference on June 9, 2022, at 8:00 a.m. (ET) in New York City. The presentation will be webcast live, with access to materials on the Chemed website. A replay will be available within 24 hours and for 90 days thereafter. Chemed operates subsidiaries including VITAS Healthcare, the largest provider of hospice care, and Roto-Rooter, a leading plumbing services provider.

At Chemed Corporation's (NYSE:CHE) 2022 annual meeting, stockholders elected 10 directors and ratified PricewaterhouseCoopers LLP as independent accountants. They approved executive compensation and the 2022 Stock Incentive Plan. A quarterly cash dividend of 36 cents per share was declared, payable on June 15, 2022, to stockholders of record as of May 26, 2022. This marks the 204th consecutive quarterly dividend in Chemed's 51 years as a public company.

Chemed Corporation (NYSE:CHE) will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 8:00 a.m. (ET) in New York City. Investors can access the live audio webcast on the company's website, with a replay available for 90 days post-event. Headquartered in Cincinnati, Ohio, Chemed operates two subsidiaries: VITAS Healthcare, a leading provider of hospice care, and Roto-Rooter, the top plumbing service in the U.S.

Investors should note the presence of forward-looking statements in the communications.

Chemed Corporation (NYSE:CHE) will present at the Bank of America Merrill Lynch 2022 Health Care Conference on May 10, 2022, at 9:20 AM PDT in Las Vegas. The presentation will be available via live webcast, which can be accessed on their website. A replay will be offered within 24 hours for 90 days. Chemed operates two main subsidiaries: VITAS Healthcare, the largest provider of end-of-life hospice care, and Roto-Rooter, a leading plumbing service.

Chemed Corporation (NYSE: CHE) reported Q1 2022 financial results, revealing a 0.6% revenue increase to $531 million. GAAP Diluted EPS rose 5.2% to $4.22, while Adjusted Diluted EPS increased 7.9% to $4.79. However, VITAS Healthcare's revenue declined 5.3% to $299 million, with significant drops in admissions and patient revenue. Conversely, Roto-Rooter experienced a 9.4% revenue growth to $231 million, contributing positively to overall performance. Chemed also repurchased shares valued at $27.4 million.